| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
YM511 targets aromatase (CYP19A1), the enzyme responsible for the conversion of androgens to estrogens. As a non-steroidal aromatase inhibitor, it binds to the enzyme's active site and blocks estrogen biosynthesis. It competitively inhibits aromatase with high potency: IC₅₀ of 0.4 nM in rat ovary and 0.12 nM in human placenta microsomes.
|
|---|---|
| ln Vitro |
In vitro, YM511 is a highly specific non-steroidal aromatase inhibitor. It competitively inhibits aromatase activities in microsomes from rat ovary (IC₅₀ = 0.4 nM) and human placenta (IC₅₀ = 0.12 nM). It weakly inhibits the synthesis of other steroid hormones and inhibits testosterone-induced breast cancer cell growth with an IC₅₀ of 0.13 nM.
|
| ln Vivo |
In vivo, YM511 decreases plasma estrogen levels into ranges induced by ovariectomy. This demonstrates its potent estrogen-lowering effects in vivo. By reducing estrogen biosynthesis, YM511 is used to study hormone-dependent cancers, particularly estrogen receptor-positive breast cancer.
|
| Enzyme Assay |
In vitro enzyme inhibition assays for YM511 are performed using microsomal preparations from rat ovary or human placenta expressing aromatase (CYP19). Enzyme activity is measured by monitoring the conversion of androstenedione to estrone using radiolabeled substrates or HPLC. The compound is incubated with the enzyme and substrate, and the IC₅₀ values (0.4 nM for rat, 0.12 nM for human) are calculated from inhibition curves.
|
| Cell Assay |
In vitro cellular assays for YM511 are performed using breast cancer cell lines, such as estrogen receptor-positive cells. Cells are treated with the compound in the presence of testosterone (an androgen substrate), and cell growth is measured using proliferation assays. The inhibition of testosterone-induced breast cancer cell growth is quantified, and the IC₅₀ (0.13 nM) is calculated.
|
| Animal Protocol |
In vivo animal experiments for YM511 are conducted in rodent models. A typical protocol involves administration of the compound via oral or intraperitoneal routes, followed by measurement of plasma estrogen levels. The compound's ability to decrease estrogen levels is assessed by comparing treated animals to ovariectomized controls. Efficacy is also evaluated in xenograft models of breast cancer.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of YM511 have been characterized in part. The compound has a molecular weight of 354.21 and molecular formula C₁₆H₁₂BrN₅. It is soluble in DMSO at 35.42 mg/mL. It should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years. Further PK details are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Toxicological data for YM511 are not extensively reported in the available literature. As a research-use compound, its safety profile has not been formally evaluated in comprehensive preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
YM511 is a highly specific, non-steroidal aromatase inhibitor with IC₅₀ values of 0.4 nM (rat ovary) and 0.12 nM (human placenta). It inhibits testosterone-induced breast cancer cell growth with an IC₅₀ of 0.13 nM. It is used in cancer research to study estrogen receptor-positive breast cancer and hormone-dependent cancers. This product is for research use only.
|
| Molecular Formula |
C16H12BRN5
|
|---|---|
| Molecular Weight |
354.21
|
| Exact Mass |
353.028
|
| CAS # |
148869-05-0
|
| PubChem CID |
177865
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.44g/cm3
|
| Boiling Point |
551.9ºC at 760 mmHg
|
| Flash Point |
287.6ºC
|
| Vapour Pressure |
3.18E-12mmHg at 25°C
|
| Index of Refraction |
1.675
|
| LogP |
3.382
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C=CC(CN(N2C=NN=C2)C2C=CC(C#N)=CC=2)=CC=1
|
| InChi Key |
GGPPBTSXFROGAE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12BrN5/c17-15-5-1-14(2-6-15)10-22(21-11-19-20-12-21)16-7-3-13(9-18)4-8-16/h1-8,11-12H,10H2
|
| Chemical Name |
4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile
|
| Synonyms |
YM 511; YM-511; YM511
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~705.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8232 mL | 14.1159 mL | 28.2318 mL | |
| 5 mM | 0.5646 mL | 2.8232 mL | 5.6464 mL | |
| 10 mM | 0.2823 mL | 1.4116 mL | 2.8232 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
